Skip to main content
Erschienen in: Annals of Hematology 12/2017

24.08.2017 | Letter to the Editor

Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21)

verfasst von: Haigang Shao, Qian Yang, Chunxiao Wu, Jiannong Cen, Suning Chen, Jinlan Pan

Erschienen in: Annals of Hematology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMed Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMed
2.
Zurück zum Zitat Kayser S, Döhner K, Krauter J et al (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117(7):2137–2145CrossRefPubMed Kayser S, Döhner K, Krauter J et al (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117(7):2137–2145CrossRefPubMed
3.
Zurück zum Zitat Bao L, Lu X, Lai Y et al (2009) Therapy-related acute myeloid leukemia after successful therapy for acute promyelocytic leukemia with t(15;17): a case report and literature review. Leuk Res 33(7):e64–e68CrossRefPubMed Bao L, Lu X, Lai Y et al (2009) Therapy-related acute myeloid leukemia after successful therapy for acute promyelocytic leukemia with t(15;17): a case report and literature review. Leuk Res 33(7):e64–e68CrossRefPubMed
4.
Zurück zum Zitat Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ et al (2015) Therapy-related myeloid neoplasms. Am J Clin Pathol 144(2):207–218CrossRefPubMed Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ et al (2015) Therapy-related myeloid neoplasms. Am J Clin Pathol 144(2):207–218CrossRefPubMed
5.
Zurück zum Zitat Heuser M (2016) Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematology Am Soc Hematol Educ Program 1:24–32 Heuser M (2016) Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematology Am Soc Hematol Educ Program 1:24–32
6.
Zurück zum Zitat Borthakur G, Lin E, Jain N et al (2009) Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115(14):3217–3221CrossRefPubMedPubMedCentral Borthakur G, Lin E, Jain N et al (2009) Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115(14):3217–3221CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Inoue K, Ogawa H, Sonoda Y et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89(4):1405–1412PubMed Inoue K, Ogawa H, Sonoda Y et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89(4):1405–1412PubMed
8.
Zurück zum Zitat Carturan S, Petiti J, Rosso V et al (2016) Variable but consistent pattern of meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. Oncotarget 7(45):74082–74096PubMedPubMedCentral Carturan S, Petiti J, Rosso V et al (2016) Variable but consistent pattern of meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. Oncotarget 7(45):74082–74096PubMedPubMedCentral
9.
Zurück zum Zitat Weber S, Haferlach T, Alpermann T et al (2016) Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia. Br J Haematol 175(5):904–916CrossRefPubMed Weber S, Haferlach T, Alpermann T et al (2016) Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia. Br J Haematol 175(5):904–916CrossRefPubMed
10.
Zurück zum Zitat Sidney LE, Branch MJ, Dunphy SE et al (2014) Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 32(6):1380–1389CrossRefPubMedPubMedCentral Sidney LE, Branch MJ, Dunphy SE et al (2014) Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 32(6):1380–1389CrossRefPubMedPubMedCentral
Metadaten
Titel
Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21)
verfasst von
Haigang Shao
Qian Yang
Chunxiao Wu
Jiannong Cen
Suning Chen
Jinlan Pan
Publikationsdatum
24.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 12/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3110-y

Weitere Artikel der Ausgabe 12/2017

Annals of Hematology 12/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.